Cargando…

Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL

Zeta-associated protein of 70 kD (ZAP70) is a recognized adverse prognostic marker in chronic lymphocytic leukaemia (CLL) associated with enhanced B-cell receptor signalling, significantly more aggressive disease course and poor overall survival. Zeta-associated protein of 70 kD is ordinarily expres...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Shilu, Walsh, Meagan, Wilson, Caroline, Parker, Anton E, Oscier, David, Willmore, Elaine, Mann, Derek, Mann, Jelena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822977/
https://www.ncbi.nlm.nih.gov/pubmed/22151263
http://dx.doi.org/10.1111/j.1582-4934.2011.01503.x
_version_ 1782290487077502976
author Amin, Shilu
Walsh, Meagan
Wilson, Caroline
Parker, Anton E
Oscier, David
Willmore, Elaine
Mann, Derek
Mann, Jelena
author_facet Amin, Shilu
Walsh, Meagan
Wilson, Caroline
Parker, Anton E
Oscier, David
Willmore, Elaine
Mann, Derek
Mann, Jelena
author_sort Amin, Shilu
collection PubMed
description Zeta-associated protein of 70 kD (ZAP70) is a recognized adverse prognostic marker in chronic lymphocytic leukaemia (CLL) associated with enhanced B-cell receptor signalling, significantly more aggressive disease course and poor overall survival. Zeta-associated protein of 70 kD is ordinarily expressed in T cells where it has a crucial role in T-cell receptor signalling, whereas its aberrant expression in CLL leads to enhanced B-cell receptor signalling and significantly more aggressive disease course. Although much is known about the activation of ZAP70 following engagement of T-cell receptor, there are little data on the regulation of ZAP70 gene expression in normal T cells or CLL. To understand the molecular events underpinning epigenetic regulation of ZAP70 gene in CLL, we have defined ZAP70 promoter region and outlined the regions crucial in regulating the gene activity. Following a direct comparison of ZAP70+ and ZAP70− primary CLLs, we show ZAP70 promoter in expressing CLLs to be associated with a spectrum of active histone modifications, some of which are tightly linked to aberrant DNA methylation in CLL. Cross-talk between histone modifications and reduced DNA methylation culminates in transcriptional de-repression of ZAP70. Moreover, treatment with histone deacetylase (HDAC) and DNA methylation inhibitors results in recovery of ZAP70 expression, which provides a possible explanation for the failure of HDAC inhibitors in CLL treatment and might serve as a cautionary warning for their future use in treatment of this leukaemia.
format Online
Article
Text
id pubmed-3822977
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-38229772015-03-27 Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL Amin, Shilu Walsh, Meagan Wilson, Caroline Parker, Anton E Oscier, David Willmore, Elaine Mann, Derek Mann, Jelena J Cell Mol Med Original Articles Zeta-associated protein of 70 kD (ZAP70) is a recognized adverse prognostic marker in chronic lymphocytic leukaemia (CLL) associated with enhanced B-cell receptor signalling, significantly more aggressive disease course and poor overall survival. Zeta-associated protein of 70 kD is ordinarily expressed in T cells where it has a crucial role in T-cell receptor signalling, whereas its aberrant expression in CLL leads to enhanced B-cell receptor signalling and significantly more aggressive disease course. Although much is known about the activation of ZAP70 following engagement of T-cell receptor, there are little data on the regulation of ZAP70 gene expression in normal T cells or CLL. To understand the molecular events underpinning epigenetic regulation of ZAP70 gene in CLL, we have defined ZAP70 promoter region and outlined the regions crucial in regulating the gene activity. Following a direct comparison of ZAP70+ and ZAP70− primary CLLs, we show ZAP70 promoter in expressing CLLs to be associated with a spectrum of active histone modifications, some of which are tightly linked to aberrant DNA methylation in CLL. Cross-talk between histone modifications and reduced DNA methylation culminates in transcriptional de-repression of ZAP70. Moreover, treatment with histone deacetylase (HDAC) and DNA methylation inhibitors results in recovery of ZAP70 expression, which provides a possible explanation for the failure of HDAC inhibitors in CLL treatment and might serve as a cautionary warning for their future use in treatment of this leukaemia. Blackwell Publishing Ltd 2012-09 2012-08-23 /pmc/articles/PMC3822977/ /pubmed/22151263 http://dx.doi.org/10.1111/j.1582-4934.2011.01503.x Text en Copyright © 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.
spellingShingle Original Articles
Amin, Shilu
Walsh, Meagan
Wilson, Caroline
Parker, Anton E
Oscier, David
Willmore, Elaine
Mann, Derek
Mann, Jelena
Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL
title Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL
title_full Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL
title_fullStr Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL
title_full_unstemmed Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL
title_short Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL
title_sort cross-talk between dna methylation and active histone modifications regulates aberrant expression of zap70 in cll
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822977/
https://www.ncbi.nlm.nih.gov/pubmed/22151263
http://dx.doi.org/10.1111/j.1582-4934.2011.01503.x
work_keys_str_mv AT aminshilu crosstalkbetweendnamethylationandactivehistonemodificationsregulatesaberrantexpressionofzap70incll
AT walshmeagan crosstalkbetweendnamethylationandactivehistonemodificationsregulatesaberrantexpressionofzap70incll
AT wilsoncaroline crosstalkbetweendnamethylationandactivehistonemodificationsregulatesaberrantexpressionofzap70incll
AT parkerantone crosstalkbetweendnamethylationandactivehistonemodificationsregulatesaberrantexpressionofzap70incll
AT oscierdavid crosstalkbetweendnamethylationandactivehistonemodificationsregulatesaberrantexpressionofzap70incll
AT willmoreelaine crosstalkbetweendnamethylationandactivehistonemodificationsregulatesaberrantexpressionofzap70incll
AT mannderek crosstalkbetweendnamethylationandactivehistonemodificationsregulatesaberrantexpressionofzap70incll
AT mannjelena crosstalkbetweendnamethylationandactivehistonemodificationsregulatesaberrantexpressionofzap70incll